Jasper therapeutics, inc. JSPR.US Overview
JSPR AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
JSPR Current Performance
-0.66%
Jasper therapeutics, inc.
2.83%
Avg of Sector
-0.07%
S&P500
JSPR Key Information
JSPR Financial Forecast
Unit : USD
JSPR Earnings Table
JSPR Profile
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Price of JSPR
JSPR FAQ
When is JSPR's latest earnings report released?
The most recent financial report for Jasper therapeutics, inc. (JSPR) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JSPR’s short-term business performance and financial health. For the latest updates on JSPR’s earnings releases, visit this page regularly.
How much debt does JSPR have?
As of the end of the reporting period, Jasper therapeutics, inc. (JSPR) had total debt of 2.59M, with a debt ratio of 0.04. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company’s capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does JSPR have?
At the end of the period, Jasper therapeutics, inc. (JSPR) held Total Cash and Cash Equivalents of 49.22M, accounting for 0.85 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is JSPR's EPS continuing to grow?
According to the past four quarterly reports, Jasper therapeutics, inc. (JSPR)’s earnings per share (EPS) shows a declining trend, with the latest EPS at -1.41. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of JSPR?
Jasper therapeutics, inc. (JSPR)’s Free Cash Flow (FCF) for the period is -22.84M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 44.9% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.